SENORESSenores Pharmaceuticals Ltd.

    Senores Pharmaceuticals Ltd: results and news

    Every Senores Pharmaceuticals Ltd filing with the NSE and BSE that Blacklitt has written about, explained in plain words and linked to the filing, newest first: earnings, guidance, management change.

    3 articles · pharmaceuticals · Latest 29 Oct 2026

    Two empty glass test tubes lying on a grey surface, one with a few dark specks inside.

    SENORESSenores Pharmaceuticals Ltd.

    Senores Pharmaceuticals Q2 FY27 Results: Consolidated Net Profit ₹36.60 Crore on Total Income of ₹201 Crore

    Senores Pharmaceuticals (NSE: SENORES) reported consolidated total income of ₹201.27 crore and net profit of ₹36.60 crore for the quarter ended 30 Sep 2026, it said in a filing on 29 Oct 2026. Standalone total income was ₹50.41 crore and standalone net profit ₹7.72 crore for the same quarter.

    • Earnings
    • pharmaceuticals

    Blacklitt Research3 min read

    SENORESSenores Pharmaceuticals Ltd

    Senores Pharmaceuticals’ board re-appoints its Managing Director and a Whole Time Director for three years

    Senores Pharmaceuticals Limited has told the exchanges that its board, at a meeting on 13 Oct 2026, approved the re-appointment of Mr. Swapnil Jatinbhai Shah as Managing Director for three consecutive years from 15 Oct 2026, and of Mr. Chetan Bipinchandra Shah as Whole Time Director for three consecutive years from 10 Nov 2026. Both are liable to retire by rotation, and both are subject to shareholder approval through a postal ballot.

    • Management change
    • Pharmaceuticals

    Blacklitt Research2 min read